lunes, 28 de septiembre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 9, 2026

Biohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica

View original at globenewswire.com
Biohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica Chicago, Feb…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Abbott's FreeStyle Libre user base swelled to 7 million globally by early 2025

    80% confidence
  • The FDA cleared 253 AI-enabled medical devices in 2024 alone, bringing the total number of authorized AI devices to 1,247 by mid-2025

    80% confidence
  • Neuralink enrolled 21 participants in its PRIME clinical trial by January 2026

    80% confidence
  • Among end-users, the research & academic institutes represented more than 35% of the revenue share in 2025

    80% confidence
  • In Q3 2024, 115 patent applications were filed specifically for personal health data technologies

    80% confidence
  • Oncology applications accounted for 35 out of 100 revenue dollars in the peptide sector in 2025

    80% confidence
  • In 2025, parenteral (injectable) formulations made up 80 out of 100 peptide products

    80% confidence
  • Whoop users logged 5.7 trillion steps and 227 billion minutes of sleep by the end of 2025

    80% confidence
  • Home and personal use settings accounted for over 6 in 10 CGM units deployed in 2024

    80% confidence
  • Dexcom projected USD 4.66 billion for fiscal year 2025

    80% confidence
  • In 2025, researchers initiated 50 new clinical trials targeting Alzheimer's

    80% confidence
  • Samsung and LG held over 15,000 US patents in 2024

    80% confidence
  • CRISPR Therapeutics had established 50 active treatment centers for Casgevy by the end of 2024, with 50 patients initiating the treatment process globally

    80% confidence
  • In 2024, 31 out of 100 financing deals were Later Stage VC rounds

    80% confidence
  • 48 Phase 1 trials for neuro-cognitive drugs began in 2025, nearly doubling the count from the previous year

    80% confidence
  • Employees participating in wellness programs took fewer sick days in 56 out of 100 cases

    80% confidence
  • The global biohacking market size was valued at USD 38.05 billion in 2025 and is projected to hit the market valuation of USD 216.68 billion by 2035 at a CAGR of 19% during the forecast period 2026–2035

    80% confidence
  • For applications, the monitoring segment generated over 30.25% of the revenue share in 2025

    80% confidence
  • Vendors shipped 4.3 million smart rings globally in 2024

    80% confidence
  • 85 out of 100 large workplaces offered comprehensive wellness programs

    80% confidence
  • The United States hosted 57 out of 100 longevity companies and captured 84 out of 100 deals in 2024

    80% confidence
  • North America led the market with the highest revenue share of 40.5% in 2025

    80% confidence
  • By September 2025, trial participants had logged 2,000 cumulative days and 15,000 hours of active BCI engagement

    80% confidence
  • Longevity discovery platforms alone attracted USD 2.65 billion in 2024

    80% confidence
  • In 2024, 9 out of 10 corporate wellness programs incorporated digital tracking elements

    80% confidence
  • Investors closed 325 deals in the longevity biotech sector in 2024, with the first quarter alone attracting USD 3.74 billion in funding

    80% confidence
  • Intellia Therapeutics enrolled 765 participants in its ongoing Phase 3 MAGNITUDE trial in 2025

    80% confidence
  • Users with HbA1c levels above 6.5 saw significant reductions after adhering to InsideTracker recommendations based on 5-year retrospective data from 20,000 users

    80% confidence
  • Dexcom G7 trials showed that 95 out of 100 participants successfully wore the device for the full 15-day duration

    80% confidence
  • Levels had served more than 60,000 members and amassed hundreds of millions of glucose data points

    80% confidence

Data points we hold from this source

U.S. Food and Drug Administration · total ai devices authorized1247 count
U.S. Food and Drug Administration · ai devices cleared 2024253 count
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Vertical AI Agents Attract a Funding Wave Across Fintech-Adjacent Industries
A cluster of AI-native startups applying autonomous agents to narrow, operational problems — hotel front-desk staffing (Dextr AI), identity/fraud risk for financial institutions (Baselayer), insurance distribution (Napo, Connie Health, MGT Insurance) — closed seed-to-Series A rounds within days of each other in September 2026, with CB Insights running a coordinated CEO interview series to spotlight them. The pattern points to agentic AI maturing from generic chat tools into vertical, revenue-generating products, with identity verification for AI agents themselves (Baselayer) emerging as a new fintech infrastructure category responding directly to AI-driven fraud risk.
Nuestra lectura de los datos ›
Señales que seguimos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,984
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,984 hechos verificados con la fuente5,306 documentos fuente archivados
Consulta estos datos → isubstrate.com
Biohacking Market to Reach US$ 216.68 Billion by 2035 Driven by Metabolic Monitoring, Wearable Diagnostics, and Personalized Health Optimization | Astute Analytica — Source | Via News | es.VIA.NEWS